AIE regimen
Term · Oncology and biomedicine · MLC-T-ONC-009734
A regimen consisting of cytarabine (Ara-C), idarubicin and etoposide, used as an induction treatment for pediatric acute myeloid leukemia (AML). High-dose cytarabine/etoposide/idarubicin regimen may be used for the treatment of AML.
| Identifier | MLC-T-ONC-009734 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | AIE |
| Synonyms | AraC-idarubicin-etoposide regimen; cytarabine-idarubicin-etoposide regimen; MRC AML10 study-AIE regimen |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009734",
"term": "AIE regimen",
"field": "Oncology and biomedicine",
"definition": "A regimen consisting of cytarabine (Ara-C), idarubicin and etoposide, used as an induction treatment for pediatric acute myeloid leukemia (AML). High-dose cytarabine/etoposide/idarubicin regimen may be used for the treatment of AML.",
"abbreviation": "AIE",
"synonyms": [
"AraC-idarubicin-etoposide regimen",
"cytarabine-idarubicin-etoposide regimen",
"MRC AML10 study-AIE regimen"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/aie-regimen/"
}
Record 569 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.